Skip to content

Early palliative care in head and neck cancer

Effect of early integration of specialized palliative care into standard oncologic treatment on the quality of life of patients with advanced head and neck cancers: A randomized controlled trial.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/03/006693
Enrollment
180
Registered
2016-03-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx Health Condition 2: null- Patients diagnosed with a squamous cell cancer of head and neck region in an advanced stage receiving palliative-intent chemotherapy.

Interventions

Intervention1: Early Palliative care arm: Patient will receive specialist palliative care along with standard oncological treatment. Patients in this arm will consult Palliative care team along with P

Sponsors

Tata Memorial Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Patients with histological confirmed squamous cell carcinoma of head and neck cancer in stage 4. • ECOG 0, 1 or 2. • Planned for treatment with palliative intent. • Age more than 18 years. • Understands Hindi, Marathi or English. • willing for follow-up.

Exclusion criteria

Exclusion criteria: • Patients with surgically resectable tumors. • Planned for definitive radiotherapy. • Uncontrolled co morbidities, such as uncontrolled diabetes mellitus, uncontrolled hypertension. • Already receiving care from palliative care services.

Design outcomes

Primary

MeasureTime frame
Change in quality of life, measured using FACIT HN.Timepoint: 03 Months after intial visit.

Secondary

MeasureTime frame
Change in quality of life measured using FACIT HN.Timepoint: 4 and 8 weeks after randomization;Changes in symptom burden using Edmonton symptom assessment scale (ESAS-r). Timepoint: 4, 8 and 12 weeks after randomization.;Overall survival.Timepoint: every month via telephone until the study ends/ Death of patient.

Countries

India

Contacts

Public ContactM A Muckaden

Tata Memorial Hospital, Mumbai

doctorpsinghai@gmail.com022-24177148

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 18, 2026